Sebastian Hachizovu

Sebastian Hachizovu

Auto-generated profile, based on publicly available information

Sebastian Hachizovu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MCMike Chaponda
Mike Chaponda
JGJonathan Gwasupika
Jonathan Gwasupika
SHSebastian Hachizovu
Sebastian Hachizovu
MNMichael Nambozi
Michael Nambozi
ECEnesia Banda Chaponda
Enesia Banda Chaponda
RCR. Matthew Chico
R. Matthew Chico
Background: Despite widespread Plasmodium falciparum resistance, intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine is more protective against adverse pregnancy and birth outcomes compared to IPTp with dihydroartemisinin–piperaquine, even though dihydroartemisinin–piperaquine is superior against malaria-related outcomes. We assessed whether adding metronidazole to sulfadoxine–pyrimethamine is more protective against adverse pregnancy and birth outcomes compared to IPTp with dihydroartemisinin–piperaquine in an area of high malaria transmission and parasite resistance to sulfadoxine–pyrimethamine, and where curable sexually transmitted infections (STIs) in pregnancy, including bacterial vaginosis, are common. Methods: From December 2019 to March 2022, we enrolled pregnant women without HIV into ASPIRE, an individually randomised, double-blinded, three-arm, partly placebo-controlled trial in Zambia. Participants received monthly IPTp with standard sulfadoxine–pyrimethamine (3 tablets 500mg sulfadoxine and 25mg pyrimethamine) plus placebo metronidazole in Arm 1, or standard sulfadoxine–pyrimethamine plus metronidazole (4 tablets 500mg) in Arm 2, or dihydroartemisinin-piperaquine plus metronidazole (3 tablets 40mg dihydroartemisinin and 320mg piperaquine once daily for 3 consecutive days) plus metronidazole (4 tablets 500mg) in Arm 3. The primary outcome was any adverse pregnancy or birth outcome (spontaneous abortion, stillbirth, low birthweight, preterm birth, or neonatal death). Secondary outcomes included components of the primary outcome, small-for-gestational age, and day 28 treatment efficacy of IPTp regimens against asymptomatic Plasmodium falciparum malaria infection and asymptomatic curable STIs. We used a modified intention-to-treat analysis for the primary outcome. ClinicalTrials.gov: NCT04189744. Findings: 5436 pregnant women were allocated to three treatment-arms. Overall, 16·3% (288/1763) of women in Arm 1 (reference) had adverse pregnancy and birth outcomes compared to 16·6% (290/1745) in Arm 2 (p=0·82), and 16·0% (281/1755) in Arm 3 (p=0·79). Of individual components of adverse pregnancy and birth outcomes in the primary outcome, none differed across arms. However, women in Arm 3 were at greater risk of delivering small-for-gestational age newborns relative to Arm 1, 28·4% (476/1678) vs 24·5% (408/1663) (p=0·01). In Arms 1, 2, and 3, the day 28 clearance of asymptomatic peripheral malaria detected by PCR was 72·1% (555/770), 71·8% (541/754), and 93·5% (722/772), respectively. In Arm 1, day 28 clearance of asymptomatic STIs by PCR, and bacterial vaginosis by microscopy using the Nugent score, were: Chlamydia trachomatis 98·4% (60/61), Neisseria gonorrhoea 84·1% (95/113), Trichomonas vaginalis 75·0% (96/128), and bacterial vaginosis 34·3% (193/563). In Arm 2, day 28 clearance rates were: C. trachomatis 89·5% (51/57), N. gonorrhoea 84·2% (96/114), T. vaginalis 87·5% (105/120), and bacterial vaginosis 53·9% (289/536). In Arm 3, day 28 clearance rates were: C. trachomatis 80·8% (42/52), N. gonorrhoea 84·9% (84/99), T. vaginalis 89·8% (115/128), and bacterial vaginosis 62·2% (335/536). Interpretation: Neither Arm 2 nor 3 were superior to Arm 1 for protection against adverse pregnancy and birth outcomes. Arm 3 was superior to Arms 1 and 2 against malaria infection, whereas all IPTp regimens reduced curable STIs, including bacterial vaginosis. Sulfadoxine-pyrimethamine may serve as an important tool fo